
Ocugen, Inc. Announces Positive DSMB Recommendation for OCU400-101 Clinical Trial
MALVERN, PA — Ocugen, Inc. (NASDAQ: OCGN) states that the independent Data and Safety Monitoring Board (DSMB) for its Phase 1/2 clinical trial of OCU400, the Company’s flagship modifier gene …
Ocugen, Inc. Announces Positive DSMB Recommendation for OCU400-101 Clinical Trial Read More